Carnegie acted as joint global co-ordinator and joint bookrunner in the initial public offering of Camurus on Nasdaq Stockholm. Camurus is a research and development based pharmaceutical company with a focus on the development and commercialisation of new and innovative pharmaceuticals for serious and chronic conditions, where there are clear medical needs and potential to significantly improve treatment. December 2015.
Healthcare
Initial public offering of Camurus AB (SE) on Nasdaq Stockholm — SEK 730 million
December 2015